The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

What Was Tested

Researchers studied Teriparatide in the context of osteoporosis and bone density in this randomized controlled trial publication.

Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.

In women receiving placebo (with calcium and vitamin D), there was an inverse relationship between baseline vertebral bone mineral density and vertebral fracture risk.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Some participants received a placebo instead of Teriparatide, giving a reference point.

The timeline in the abstract includes 65 years.

What Was Measured

Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures.

The subject headings attached to it are Age Factors, Bone Density, Osteoporosis, Postmenopausal, Risk Factors, Spinal Fractures, Spine and Teriparatide.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide in people with osteoporosis and bone density over 65 years.

The publication is from 2003 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.